Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
ActiveMax® Recombinant Human IL-7 Protein, 50µg  

ActiveMax® Recombinant Human IL-7 Protein, 50µg

ActiveMax® Recombinant Human IL-7 Protein, Asp 26 - His 177, produced in human 293 cells (HEK293), Tag free, low endotoxin, (MALS verified)

Synonym: Recombinant Human Protein, IL7,Interleukin-7

More details

IL7-H4219-50

Availability: within 7 days

540,00 €

Background
Interleukin 7 is also known as IL7, IL-7, and is a hematopoietic growth factor secreted by stromal cells in the red marrow and thymus. It is also produced by keratinocytes, dendritic cells, hepatocytes, neurons, and epithelial cells, but is not produced by lymphocytes. IL-7 stimulates the differentiation of multipotent (pluripotent) hematopoietic stem cells into lymphoid progenitor cells, It also stimulates proliferation of all cells in the lymphoid lineage (B cells, T cells and NK cells). It is important for proliferation during certain stages of B-cell maturation, T and NK cell survival, development and homeostasis. IL-7 is a cytokine important for B and T cell development. This cytokine and the hepatocyte growth factor (HGF) form a heterodimer that functions as a pre-pro-B cell growth-stimulating factor. IL-7 binds to the IL-7 receptor, a heterodimer consisting of Interleukin-7 receptor alpha and common gamma chain receptor. Il-7 promotes hematological malignacies (acute lymphoblastic leukemia, T cell lymphoma). Elevated levels of IL-7 have also been detected in the plasma of HIV-infected patients. IL-7 as an immunotherapy agent has been examined in many pre-clinical animal studies and more recently in human clinical trials for various malignancies and during HIV infection. IL-7 could also be beneficial in improving immune recovery after allogenic stem cell transplant.

Source
ActiveMax® Recombinant Human IL-7, Tag Free (IL7-H4219) is expressed from human 293 cells (HEK293). It contains AA Asp 26 - His 177 (Accession # P13232).
Predicted N-terminus: Asp 26

Molecular Characterization
This protein carries no "tag".
The protein has a calculated MW of 17.4 kDa. The protein migrates as 24 kDa and 25-28 kDa under reducing (R) condition (SDS-PAGE) due to different glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>98% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 6 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

References

(1) Recombinant Mycobacterium smegmatis delivering a fusion protein of human macrophage migration inhibitory factor (MIF) and IL-7 exerts an anticancer effect by inducing an immune response against MIF in a tumor-bearing mouse model
Jeong, Lee, Seo et al
J Immunother Cancer (2021) 9 (8)
(2) Defining Potential Therapeutic Targets in Coronavirus Disease 2019: A Cross-Sectional Analysis of a Single-Center Cohort
Arulkumaran, Snow, Kulkarni et al
Crit Care Explor (2021) 3 (8), e0488
(3) Gene-Edited Interleukin CAR-T Cells Therapy in the Treatment of Malignancies: Present and Future
Zhang, Miao, Ren et al
Front Immunol (2021) 12, 718686
Showing 1-3 of 6991 papers.
Please refer to product data sheet.